Morgan Stanley analyst Sean Laaman assumed coverage of Erasca (ERAS) with an Overweight rating and $4 price target The firm sees potential upside from naporafenib and readthroughs in the (K)RAS space, the analyst tells investors in a research note. Morgan Stanley also says it is encouraged by the preclinical profiles of ERAS-0015 and ERAS-4001, but notes that it will take time for clinical data to be generated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue